Back to Search Start Over

Validation of a genotype-based algorithm that identifies individuals with low, intermediate, and high serum CA19-9 levels in cancer-free individuals and in patients with colorectal cancer.

Authors :
Wannhoff A
Werner S
Tao S
Brenner H
Gotthardt DN
Source :
Journal of gastrointestinal oncology [J Gastrointest Oncol] 2022 Aug; Vol. 13 (4), pp. 1711-1721.
Publication Year :
2022

Abstract

Background: Serum levels of Carbohydrate antigen CA19-9 are determined by the genotype of fucosyltransferases 2 and 3. To validate, possibly modify, and improve a grouping algorithm based on these genotypes.<br />Methods: CA19-9 levels genotypes and of fucosyltransferase 2 and 3 were analyzed in cancer-free and colorectal cancer patients. Patients were assigned to groups with low (group A), intermediate (B), or high (C) CA19-9 biosynthetic activity based on a previously developed grouping algorithm based on genotype of fucosyltransferases 2 and 3.<br />Results: Three hundred thirty-eight patients were included (n=177 cancer-free). Of cancer-free patients 7.9%, 75.7%, and 16.4% were assigned to groups A, B, and C, respectively. In colorectal cancer patients it 7.5%, 77.0%, and 15.5%, respectively. There were significant differences between median CA19-9 levels in the three groups (P<0.001) in both cohorts. The T59G single-nucleotid polymorphism in fucosyltransferase 3 had a significant influence on CA19-9 levels in cancer-free group B patients, which led to establishment of subgroups B1 and B2. However, no difference in CA19-9 levels between these subgroups was found in colorectal cancer patients. A receiver-operating characteristic showed similar areas under the curve for original group B as well as for subgroups B1 and B2.<br />Conclusions: The grouping algorithm based on genotype of fucosyltransferases 2 and 3, which defines groups with distinct CA19-9 serum levels, was validated in cancer-free patients and in colorectal cancer patients. No clinically relevant improvement to the grouping algorithm was identified.<br />Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-22-310/coif). AW is co-owner of a patent for a medical analysis system assessing the risk of cancer based upon CA19-9 or CEA and FUT2- and FUT3 genotype. HB reports funding from German Research Council (DFG). DNG is co-owner of a patent for a medical analysis system assessing the risk of cancer based upon CA19-9 or CEA and FUT2- and FUT3 genotype. The other authors have no conflicts of interest to declare.<br /> (2022 Journal of Gastrointestinal Oncology. All rights reserved.)

Details

Language :
English
ISSN :
2078-6891
Volume :
13
Issue :
4
Database :
MEDLINE
Journal :
Journal of gastrointestinal oncology
Publication Type :
Academic Journal
Accession number :
36092337
Full Text :
https://doi.org/10.21037/jgo-22-310